Polidocanol is a sclerosing agent used for the treatment of uncomplicated spider veins and uncomplicated reticular veins, all less than 3 mm in diameter, in the lower extremity. It is marketed under the brand names Asclera and Varithena.
- Mechanism
- Curator reviewed
When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.
- Primary indication
- Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.Curator reviewed · 7 structured indications
- Formula / weight
- C30H62O10 · 582.8073 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2010
- Also known as
- Aethoxy-sklerol · Laureth 9 · Laureth-9 · Lauromacrogol 400 · Macrogol 9 lauryl ether
- Code names
- 10XB-101 · 3055-99-0
- Brand names
Resolves to
ONJQDTZCDSESIW-UHFFFAOYSA-NSMILESCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOWhat you can answer from here — as of September 17, 2026
Which other approved drugs treat the same conditions as Polidocanol, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account